"With sluggish economic growth expectations, companies need to make acquisitions to boost profitability; the recent sell-off has made takeover targets more affordable and represents an ideal time to pounce," says Louis Basenese.

In a report from White Cap Research Group, he explains, "All told, over $9 billion in deals have been announced in the US in the aftermath of the recent sell off. And for every deal that's been announced, there's at least three more offers being contemplated.

"In short, the recent sell off sent many due diligence teams into hyperdrive. Any subsequent selling should prompt the big wigs to pull the trigger on more deals before the opportunities disappear.

"And that's decidedly good news for these four of our White Cap recommendations: Acme Packet (APKT), Medidata Solutions (MDSO), CAMAC Energy (CAK), and Chemed Corp. (CHE).

Two growth stock specialists have turned bullish on the prospects for medical equipment maker Varian Medical Systems (VAR), despite uncertainty surrounding health care legislation.

Here's a look at the company from Louis Basenese, senior analyst with The Oxford Club, along with commentary from Mark Skousen, from his specialty service, The Turnaround Alert.

Mark Skousen suggests, "One stock that should benefit from 'ObamaCare' is Varian Medical Systems, the world's leader in radiation technology and X-ray imaging.

"Diageo (NYSE: DEO), the world's largest spirits maker, offers solid and safe dividend, as well as the potential for strong capital appreciation," says Louis Basenese.

The senior analyst for the prestigious The Oxford Club suggests, "Moreover, investors can also prepare for a US dollar decline by buying these shares." Here's his bullish outlook.

"Headquartered in London, roughly 70% of the company's sales come from outside the United States. So any dollar dip will increase the value of our ADRs.

"Moreover, management concedes that positive currency tailwinds in the other countries where Diageo sells spirits will help the company easily grow earnings by double digits this year.

"As my high school football coach always quipped, 'Offense may win fans, but defense wins games,'" says leading growth stock expert Louis Basenese.

Here, the Oxford Club associate investment director takes a look at his three favorite defense stocks, noting, "When it comes to investing in the current environment, I'm convinced that you can't go wrong with this trio of companies."

"In my view, this sector willl never fall out of favor. The recent development with Russia serves to underscore another point I've been making for years. We always have to be prepared.

"Or, put another way, there will never be a good time for defense cuts, lest we want to leave our country vulnerable.Add it all up, and we can expect defense companies to enjoy steady demand. Even in the face of a recession.

"As the CEO of Rockwell notes, there has been absolutely no fallout in the defense industry as a result of the worldwide credit meltdown or other economic woes. So here's a quick run-down on the three defense companies we prefer for investors.

"I think now is a particularly opportune time to buy the world's largest fast-food company, YUM! Brands (NYSE: YUM) ," says Louis Basenese.

The associate investment director and contributing editor to The Oxford Club observes, "YUM Brands operates 35,000 restaurants under the KFC, Taco Bell and Pizza Hut brands." Here's his review of the firm's outlook, including its expanding role in China.

"For starters, YUM keeps extending its streak of impressive results. For the seventh quarter in a row it beat expectations. Earnings per share increased 16% for the quarter and 28% year-to-date. Not to be overlooked either is the fact YUM raised guidance. Again.

"This quarter, fewer than 5% of companies in the S&P 500 can boast this triple whammy (beating earnings and revenue estimates and raising guidance). Ironically, while most of the other triple-whammy stocks enjoyed hefty single- and double-digit run-ups on the announcements, YUM sold off.

"And here's where I think most investors are missing the boat, and once again focusing too heavily on the short term. Yes, YUM's in a pinch. Food costs are rising and consumers are spending less.

"The pipelines of most Big Pharmas are bone dry; last year, the FDA approved the lowest number of new drugs (19) since 1983," notes Louis Basenese, editor of The Oxford Club.

"But opportunity always lurks in the wreckage, and one Big Pharma, in particular, is being unfairly punished." Here's his bullish outlook on Novartis (NYSE: NVS).

"Unlike others in the sector, Novartis doesn't suffer from an empty pipeline. It's launched more drugs globally than any other firm in the past seven years. It has more than 100 projects in phase II (or later) trials. And it expects to file at least six new drug applications this year alone.

"Plus, its products cover all bases, from vaccines to specialized drugs to generics to eye-care products, even animal health items. And most are enjoying rapidly expanding sales.

"Moreover, the company maintains a fortress-like financial position that includes a $10.8 billion cash horde. Management keeps raising the dividend, for 11 years and counting. And it recently announced a massive $9 billion stock-repurchase plan, too. Hardly the hallmarks of a sickly stock.

Referring to his long-recommended position in YUM! Brands (NYSE: YUM), Louis Basenese exclaims, "I've spent 1,308 days tracking its price movements and written 11,239 words expounding its virtues."

Indeed, the associate Investment Director for The Oxford Club states, "If I could only recommend one stock to own for the next decade, hands down YUM! Brands would be the one."

"YUM! Brands, operator of KFC, Pizza Hut and Taco Bell, is quietly transforming itself into an international juggernaut. Today, roughly half of its operations and profits come from outside our borders. Tomorrow (okay, not that quickly, but soon), more than two thirds of its business will be based outside the United States.

"And the transition and timing couldn't be more perfect. More than half the word's investable market capitalization is now outside the United States. And that percentage keeps growing.

"When I evaluate the underlying fundamentals in the financial sector, I find myself ready to back up the truck," notes Louis Basenese, editor with The Oxford Club. Here he looks at a financial ETF.

"Recently GE shocked the world when it missed earnings expectations by seven cents because of difficulties in its financial services business, the seventh largest in the United States. Then Wachovia posted a worse-than expected $1.1 billion loss.

"Next was Washington Mutual which reported a $1.14 billion quarterly loss, worse than expected. And Merrill Lynch had a quarterly loss of $1.96 billion, also worse than expectations.

"Not to be outdone, the bottom of the line-up, regional banks (Comerica Inc., KeyCorp and PNC Financial Services Group) also struck out, reporting worse than expected first-quarter net income and/or mounting credit-loss provisions and net charge-offs.

"Remarkably, the Financial Select Sector SPDR (ASE: XLF) has barely budged. Indeed, its 15% higher than where it was when Bear Stearns collapsed.

"The recent fits and spasms of the stock market predict tough times ahead; and ironically, that's good news for Raytheon (NYSE: RTN)," says Louis Basenese, Oxford Club Associate Investment Director.

In The Oxford Insight, he notes, "When stocks are anticipating a recession, the best offense is often defense stocks -- and there's plenty of reason to expect this defense contractor to shine, even if a recession is confirmed."

"Defense will likely remain one of the largest budget items for the United States, regardless of which political party wins the fall election. And, according to JP Morgan Securities, the defense outlays of the United States actually increase, by an average of 6.5% during recession years since 1945.

"So in the end, recession or not, as the world's fifth largest defense contractor, Raytheon's sure to enjoy steady demand.

"I'm sure you've recently read, all about the large spy satellite that became disabled and was poised to re-enter earth's atmosphere with a dangerous load of toxic fuel. What few know is that Raytheon's Standard Missile-3 was specially modified to intercept the target 153 miles over the Pacific Ocean.